Gynecologic Cancers Convergence Research Team - Stand Up To Cancer

Convergence Teams

Research  >  Research Portfolio  >  Convergence Teams  >  Gynecologic Cancers Convergence Research Team

SU2C Gynecologic Cancers Convergence Research Team: Connecting Immune Health and Tumor Biology in Gynecologic Cancers

Grant Term: January 2018–December 2020

The SU2C Gynecologic Cancers Convergence Research Team studies immune defects in gynecologic cancer patients with highly mutated tumors to gain insights into immune responsiveness. The scientists are working to predict therapeutic outcomes and tailor treatment regimens for this subset of gynecologic cancers.


Mismatch repair (MMR) deficiency, the inability to repair faulty base pairing within the DNA helix, causes mutations to accumulate in DNA as cells replicate. In gynecologic cancers, the response to immune checkpoint inhibitors has been varied and may be related to the number of mutations carried by each tumor cell. The SU2C Gynecologic Cancers Convergence Research Team hypothesizes that some tumors with a high number of mutations fail to respond to checkpoint inhibition because of an immune dysfunction related to the mechanism for MMR deficiency.

The team is conducting two clinical trials that will test a) whether tumor-intrinsic factors affect the response to checkpoint inhibition; b) whether baseline immune function and quality affect this response; and c) whether there are blood biomarkers during treatment that may reflect the tumor-immune interaction.

Understanding the mechanism that causes some gynecologic cancers to fail to respond to checkpoint inhibition has the potential to dramatically impact those patients who do not respond to current treatments.


Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.